Zobrazeno 1 - 5
of 5
pro vyhledávání: '"M. L. Vitovskaya"'
Autor:
J. A. Bespyatykh, Т. I. Vinogradova, O. A. Manicheva, N. V. Zabolotnykh, M. Z. Dogonadze, M. L. Vitovskaya, A. S. Guliaev, V. Yu. Zhuravlev, E. A. Shitikov, E. N. Ilina
Publikováno v:
Инфекция и иммунитет, Vol 9, Iss 1, Pp 173-182 (2019)
Mycobacterium tuberculosis Beijing genotype strains comprise 50–80% in Russian Federation, which are divided into the main B0/W148, CladeA, and CAO clusters based on VNTR and SNP analysis. It should be noted that such phylogenetically highly close
Externí odkaz:
https://doaj.org/article/dc7cc046fdb94b4c9cde45e95ecaab68
Autor:
M. L. Vitovskaya, N. V. Zabolotnykh, T. I. Vinogradova, S. N. Vasilyeva, A. S. Kaftyrev, B. M. Ariel, E. S. Kirillova, T. A. Novitskaya, S. V. Iskrovskiy, M. S. Serdobintsev
Publikováno v:
Travmatologiâ i Ortopediâ Rossii, Vol 0, Iss 3, Pp 80-87 (2013)
The effect of Roncoleukin on the recovery of the bone tissue in plastic operational defects (autobone+OsteoSet-T) on the model of experimental tuberculous osteites in 36 rabbits caused by drug resistant clinical strains of M. tuberculosis was studied
Externí odkaz:
https://doaj.org/article/2a257be8978e4ce3a5a5a20cc100453b
Autor:
P K Yablonskiy, T I Vinogradova, Yu N Levashev, M V Pavlova, E K Zilber, A A Starshinova, N V Sapozhnikova, I V Chernokhaeva, L I Archakova, N V Zabolotnykh, M L Vitovskaya
Publikováno v:
Терапевтический архив, Vol 88, Iss 3, Pp 111-115 (2016)
The paper sets forth the stages of design and introduction of the new Russian tuberculosis (TB) drug perchlozon registered in the Russian Federation in 2012. Based on the results of Phases I-III clinical trials, the authors evaluate the efficacy and
Externí odkaz:
https://doaj.org/article/fb038c632bd145359e573e43d0d89e97
Autor:
D S, Sukhanov, T I, Vinogradova, S N, Demidik, N V, Zabolotnyh, S N, Vasilieva, A L, Kovalenko, M L, Vitovskaya
Publikováno v:
Patologicheskaia fiziologiia i eksperimental'naia terapiia. (1)
The results of pre-clinical research of cycloferon, remaxol and runihol on the model of experimental generalized tuberculosis, caused by the MBT with a different spectrum of drug sensitivity are presented. A considerable increase of the curative effe
Autor:
T. I. Vinogradova, N. V. Sapozhnikova, Yu. N. Levashev, Piotr Yablonskiy, I. V. Chernokhaeva, M. L. Vitovskaya, N. V. Zabolotnykh, Pavlova Mv, A. A. Starshinova, E. K. Zilber, Ludmila Archakova
Publikováno v:
Терапевтический архив, Vol 88, Iss 3, Pp 111-115 (2016)
ResearcherID
ResearcherID
The paper sets forth the stages of design and introduction of the new Russian tuberculosis (TB) drug perchlozon registered in the Russian Federation in 2012. Based on the results of Phases I-III clinical trials, the authors evaluate the efficacy and